News + Analysen
News + Adhoc
zugeh. Wertpapiere
Strukturierte Produkte
17.06.2019 23:00:00

Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

Pfizer (NYSE: PFE) is at it again. After a couple of years without any significant merger and acquisition activity, the big drugmaker announced on Monday that it's buying Array BioPharma (NASDAQ: ARRY).The price tag on the deal was great news for Array shareholders. Pfizer will pay around $48 per share in cash -- 63% above Array's Friday closing price -- for a total of around $11.4 billion. Array stock understandably skyrocketed in early trading on Monday.But how great is this news for Pfizer shareholders? That's a tougher question to answer. Pfizer's share price slipped a little in the initial hours of trading after the transaction was announced. The problem for investors is that the Array acquisition won't pay off anytime soon.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Array BioPharma Inc.mehr Analysen

07.02.18 Array BioPharma Buy Stifel, Nicolaus & Co., Inc.
22.01.18 Array BioPharma Buy Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

Energiemarkt-Update: Quo vadis Rohölpreis? | BX Swiss TV

Finanzen.net News